본문 바로가기
HOME> 논문 > 논문 검색상세

논문 상세정보

A Pilot Study of Bortezomib in Korean Patients with Relapsed or Refractory Myeloma

Lee, Keun-Wook    (Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea.   ); Yun, Tak    (Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea.   ); Song, Eun Kee    (Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea.   ); Na, Im il    (Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea.   ); Shin, Hyunchoon    (Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea.   ); Bang, Soo-Mee    (Department of Internal Medicine, Gachon Medical School, Incheon, Korea.   ); Lee, Jae Hoon    (Department of Internal Medicine, Gachon Medical School, Incheon, Korea.   ); Lee, Seung Tae    (Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.   ); Kim, Jee Hyun    (Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea.   ); Yoon, Sung-Soo    (Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea.   ); Lee, Jong Seok    (Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea  ); Park, Seonyang   Kim, Byoung Kook   Kim, Noe Kyeong  
  • 초록

    Recent clinical trials showed that bortezomib, a novel proteasome inhibitor, had therapeutic activity in multiple myeloma. However, there was no data about the feasibility of bortezomib in Korean patients. We performed a pilot study of bortezomib in patients with relapsed or refractory myeloma (1.3 mg/m 2 twice weekly for 2 week in a 3-week cycle). Seven patients were enrolled. The median age of patients was 59 yr. All patients previously received VAD (vincristine, doxorubicin and dexamethasone) and thalidomide chemotherapy. Three patients previously received alkylator-containing chemotherapy and 4 patients, autologous stem cell transplantation. Bortezomib monotherapy resulted in 3 partial remissions (43%), 3 no changes (43%) and 1 progressive disease (14%). One patient who had no response to bortezomib monotherapy experienced partial remission after addition of dexamethasone to bortezomib. The most common serious toxicity was thrombocytopenia (grade 3/4, 10 of 20 cycles (50%)) and grade 3 peripheral neuropathy was developed in 2 of 20 cycles (10%). Drug-related adverse event led to discontinuation of bortezomib in 1 patient. There was no treatment related mortality. Overall, bortezomib seems to be effective and feasible. Conduction of larger clinical studies on Korean patients is necessary to characterize clinical efficacy and safety of bortezomib more precisely.


  • 주제어

    Multiple Myeloma .   Drug Therapy .   bortezomib .   Velcade .   Proteasome Endopeptidase Complex .   Protease Inhibitors.  

 활용도 분석

  • 상세보기

    amChart 영역
  • 원문보기

    amChart 영역

원문보기

유료다운로드
  • 원문이 없습니다.

유료 다운로드의 경우 해당 사이트의 정책에 따라 신규 회원가입, 로그인, 유료 구매 등이 필요할 수 있습니다. 해당 사이트에서 발생하는 귀하의 모든 정보활동은 NDSL의 서비스 정책과 무관합니다.

원문복사신청을 하시면, 일부 해외 인쇄학술지의 경우 외국학술지지원센터(FRIC)에서
무료 원문복사 서비스를 제공합니다.

NDSL에서는 해당 원문을 복사서비스하고 있습니다. 위의 원문복사신청 또는 장바구니 담기를 통하여 원문복사서비스 이용이 가능합니다.

이 논문과 함께 출판된 논문 + 더보기